Exercise: it's the real thing!
John A Hawley,
John O Holloszy,
John A Hawley
School of Medical Sciences, RMIT University, Bundoora, Australia
Search for more papers by this authorJohn O Holloszy
Division of Geriatrics and Gerontology, Washington University, St. Louis, Missouri, USA.
Search for more papers by this authorJohn A Hawley,
John O Holloszy,
John A Hawley
School of Medical Sciences, RMIT University, Bundoora, Australia
Search for more papers by this authorJohn O Holloszy
Division of Geriatrics and Gerontology, Washington University, St. Louis, Missouri, USA.
Search for more papers by this authorJA Hawley, Exercise Metabolism Group, School of Medical Sciences, Building 223.2.52, RMIT University, PO Box 71, Bundoora, Victoria 3083, Australia. E-mail: [email protected], Phone: +61-3-9925-7353, Fax: +61-3-9467-8181.
Abstract
The epidemic emergence of modern chronic diseases largely stems from the adoption of a sedentary lifestyle and excess energy intake. However, it has long been known that regular physical activity induces multiple adaptations within skeletal muscle and other organs and these adaptations have positive outcomes for the prevention and treatment of many metabolic disorders. In recognition of such benefits, a recent goal of industry-funded research is to discover orally active compounds that mimic the effects of exercise training, so-called “exercise pills”. This article provides an overview of the role of skeletal muscle in health and disease and discusses whether “exercise mimetics” have any potential to combat metabolic diseases.
REFERENCES
- 1 Booth FW, Laye MJ, Lees SJ, Rector RS, Thyfault JP. Reduced physical activity and risk of chronic disease: the biology behind the consequences. Eur J Appl Physiol. 2008; 102: 381–390.
- 2 Booth FW, Lees SJ. Fundamental questions about genes, inactivity and chronic diseases. Physiol Genomics. 2007; 28: 146–157.
- 3 Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. Metabolic responses to reduced daily steps in healthy nonexercising men. JAMA. 2008; 19: 1261–1263.
- 4 Booth FW, Gordon SE, Carlson CJ, Hamilton MT. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol. 2000; 88: 774–787.
- 5 Centers for Disease Control and Prevention. Physical Activity for Everyone: The Importance of Physical Activity. 2006:Available at: http://www.cdc.gov/nccdphp/dnpa/physical/importance/index.htm. Accessed January 16, 2008.
- 6 Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med. 1998; 49: 235–261.
- 7 Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev. 2004; 20: 383–393.
- 8 Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem. 2006; 42: 105–117.
- 9 American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998; 30: 975–991.
- 10 DeFronzo RA, Gunnarsson R, Björkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985; 76: 149–155.
- 11 Bergström J, Hultman E. Muscle glycogen synthesis after exercise: an enhancing factor localized to the muscle cells in man. Nature. 1966; 16: 309–310.
- 12 Saltin B, Henriksson J, Nygaard E, Andersen P, Jansson E. Fiber types and metabolic potentials of skeletal muscles in sedentary man and endurance runners. Ann N Y Acad Sci. 1977; 301: 3–29.
- 13 Zierath JR, Hawley JA. Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol. 2004; 2: e348.
- 14 Costill DL, Daniels J, Evans W, Fink W, Krahenbuhl G. Skeletal muscle enzymes and fiber composition in male and female track athletes. J Appl Physiol. 1976; 40: 149–154.
- 15 Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987; 80: 415–424.
- 16 Daugaard JR, Nielsen JN, Kristiansen S, Andersen JL, Hargreaves M, Richter EA. Fiber type-specific expression of GLUT4 in human skeletal muscle: influence of exercise training. Diabetes. 2000; 49: 1092–1095.
- 17 Henriksen EJ, Bourey RE, Rodnick KJ, Koranyi L, Permutt MA. Glucose transporter protein content and glucose transport capacity in rat skeletal muscles. Am J Physiol. 1990; 259: E593–E598.
- 18 Song XM, Ryder JW, Kawano Y, Chibalin AV, Krook A, Zierath JR. Muscle fiber type specificity in insulin signal transduction. Am J Physiol. 1999; 277: R1690–R1696.
- 19 Pette D, Hofer HW. The constant proportion enzyme group concept in the selection of reference enzymes in metabolism. Ciba Found Symp. 1980; 73: 231–244.
- 20 Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J. 1995; 9: 273–278.
- 21 Simoneau JA, Kelley DE. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol. 1997; 83: 166–171.
- 22 Papa S. Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Biochim Biophys Acta. 1996; 1276: 87–105.
- 23 Holloszy JO. Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. J Biol Chem. 1967; 242: 2278–2282.
- 24 Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 1984; 56: 831–839.
- 25 Baar K, Wende AR, Jones TE, et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002; 16: 1879–1886.
- 26 Irrcher I, Adhihetty PJ, Sheehan T, Joseph A-M, Hood DA. PPARg coactivator-1a expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations. Am J Physiol Cell Physiol. 2003; 284: C1669–C1677.
- 27 Wright DC, Han D-H, Garcia-Roves PM, Geiger PC, Jones TE, Holloszy JO. Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1a expression. J Biol Chem. 2007; 282: 194–199.
- 28 Constable SH, Favier RJ, McLane JA, Fell RD, Chen M, Holloszy JO. Energy metabolism in contracting rat skeletal muscle: adaptation to exercise training. Am J Physiol Cell Physiol. 1987; 253: C316–C322.
- 29 Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005; 307: 384–387.
- 30 Reznick RM, Zong H, Li J, et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 2007; 5: 151–156.
- 31 Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002; 51: 2944–2950.
- 32 Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006; 55(Suppl 2): S9–S15.
- 33 Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med. 2005; 2: e233.
- 34 Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34: 267–273.
- 35 Hawley JA, Lessard SJ. Mitochondrial function: use it or lose it. Diabetologia. 2007; 50: 699–702.
- 36 Holloszy JO. Skeletal muscle “mitochondrial deficiency” does not mediate insulin resistance. Am J Clin Nutr. 2009; 89(Suppl): 4635–4665.
- 37 Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem. 2006; 97: 673–683.
- 38 Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004; 18: 357–368.
- 39 Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005; 1: 361–370.
- 40 Lehman JJ, Barger PM, Kovacs A, Saffitz J, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor g coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000; 106: 847–856.
- 41 Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1a drives the formation of slow-twitch muscle fibres. Nature. 2002; 418: 797–801.
- 42 Goto M, Terada S, Kato M, et al. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. Biochem Biophys Res Commun. 2000; 274: 350–354.
- 43 Norrbom J, Sundberg CJ, Ameln H, Kraus WE, Jansson E, Gustafsson T. PGC-1a mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle. J Appl Physiol. 2004; 96: 189–194.
- 44 Knutti D, Kressler D, Kralli A. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci USA. 2001; 98: 9713–9718.
- 45 Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001; 8: 971–982.
- 46 Akimoto T, Pohnert SC, Li P, et al. Exercise stimulates Pgc-1a transcription in skeletal muscle through activation of the p38 MAPK pathway. J Biol Chem. 2005; 280: 19587–19593.
- 47 Cao W, Daniel KW, Robidoux J, et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol. 2004; 24: 3057–3067.
- 48 Bassel-Duby R, Olson EN. Signalling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006; 75: 19–37.
- 49 Hawley JA, Hargreaves M, Zierath JR. Signalling mechanisms in skeletal muscle: role in substrate selection and muscle adaptation. Essays Biochem. 2006; 42: 1–12.
- 50 Freyssenet D, Irrcher I, Connor MK, Di Carlo M, Hood DA. Calcium-regulated changes in mitochondrial phenotype in skeletal muscle cells. Am J Physiol Cell Physiol 2004; 286: C1053–C1061.
- 51 Ojuka EO, Jones TE, Han D-H, Chen M, Holloszy JO. Raising Ca2+ in L6 myotubes mimics effects of exercise on mitochondrial biogenesis in muscle. FASEB J. 2003; 17: 675–681.
- 52 Wright DC, Geiger PC, Han D-H, Jones TE, Holloszy JO. Calcium induces increases in peroxisome proliferator-activated receptor g coactivator-1a and mitochondrial biogenesis by a pathway leading to p38 mitogen-activated protein kinase activation. J Biol Chem. 2007; 282: 18793–18799.
- 53 Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda). 2006; 21: 48–60.
- 54 Rasmussen BB, Winder WW. Effect of exercise intensity on skeletal muscle malonyl-CoA and acetyl-CoA carboxylase. J Appl Physiol. 1997; 83: 1104–1109.
- 55 Yu M, Stepto NK, Chibalin AV, et al. Metabolic and mitogenic signal transduction in human skeletal muscle after intense cycling exercise. J Physiol. 2002; 546: 327–335.
- 56 Ojuka EO, Nolte LA, Holloszy JO. Increased expression of GLUT-4 and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro. J Appl Physiol. 2000; 88: 1072–1075.
- 57 Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol. 1999; 87: 1990–1995.
- 58 Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol. 2000; 88: 2219–2226.
- 59 Jorgensen SB, Treebak JT, Viollet B, et al. Role of AMPKa2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am J Physiol. 2007; 292: E331–E339.
- 60 Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1a. Proc Natl Acad Sci USA. 2007; 104: 12017–12022.
- 61 Wang Y-X, Zhang C-L, Yu RT, Cho HK, et al. Regulation of muscle fiber type and running endurance by PPARd. PLOS Biol. 2004; 2: 1532–1539.
- 62 Scarpulla RC. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene. 2002; 286: 81–89.
- 63 Hancock CR, Han D-H, Chen M, et al. High fat diets cause insulin resistance despite an increase in muscle mitochondria. PNAS. 2008; 105: 7815–7820.
- 64 Booth FW, Lees SJ. Physically active subjects should be the control group. Med Sci Sports Exerc. 2006; 38: 405–406.
- 65 Narkar VA, Downes M, Yu RT, et al. AMPK and PPARd agonists are exercise mimetics. Cell. 2008; 134: 405–415.
- 66 Musi N, Goodyear LJ. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2002; 2: 119–127.
- 67 Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signalling. J Biol Chem. 2002; 277: 23977–23980.
- 68 Horman S, Browne G, Krause U, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol. 2002; 12: 1419–1423.
- 69 Turner N, Bruce CR, Beale SM, et al. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle. Evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes. 2007; 56: 2085–2092.
- 70 Garcia-Roves PM, Huss JM, Han D-H, et al. Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle. PNAS. 2007; 104: 10709–10713.
